A pharmacokinetic analysis of molecular cardiac surgery with recirculation mediated delivery of βARKct gene therapy: developing a quantitative definition of the therapeutic window.
暂无分享,去创建一个
W. Koch | H. Stedman | M. Katz | A. Fargnoli | C. Bridges | M. Sumaroka | C. Yarnall | J. Rabinowitz
[1] M. Katz,et al. Current strategies for myocardial gene delivery. , 2011, Journal of molecular and cellular cardiology.
[2] D. Leosco,et al. GRK2 as a novel gene therapy target in heart failure. , 2011, Journal of molecular and cellular cardiology.
[3] W. Koch,et al. Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo , 2011, Gene Therapy.
[4] M. Katz,et al. Gene therapy during cardiac surgery: role of surgical technique to minimize collateral organ gene expression. , 2010, Interactive cardiovascular and thoracic surgery.
[5] W. Koch,et al. Comparative Cardiac Gene Delivery of Adeno‐Associated Virus Serotypes 1–9 reveals that AAV6 Mediates the Most Efficient Transduction in Mouse Heart , 2010, Clinical and translational science.
[6] C. Bridges. ‘Recirculating cardiac delivery’ method of gene delivery should be called ‘non-recirculating’ method , 2009, Gene Therapy.
[7] D. Mancini,et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. , 2009, Journal of cardiac failure.
[8] W. Koch,et al. Myocardial Adeno-Associated Virus Serotype 6–&bgr;ARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure , 2009, Circulation.
[9] W. Koch,et al. Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. , 2007, Journal of cardiac failure.
[10] R. Samulski,et al. Adeno-associated virus serotypes: vector toolkit for human gene therapy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] H. Sundar,et al. Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. , 2005, The Journal of thoracic and cardiovascular surgery.
[12] W. Koch,et al. Dose dependent effects of cardiac β2 adrenoceptor gene therapy1 , 2004 .
[13] Robert J Lederman,et al. Incomplete retention after direct myocardial injection , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[14] J. Michel,et al. How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? , 2001, Human gene therapy.
[15] James M. Allen,et al. Adeno-Associated Virus Type 6 (AAV6) Vectors Mediate Efficient Transduction of Airway Epithelial Cells in Mouse Lungs Compared to That of AAV2 Vectors , 2001, Journal of Virology.
[16] P. Boekstegers,et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins , 2000, Gene Therapy.
[17] P. Boekstegers,et al. Selective pressure-regulated retroinfusion of coronary veins as an alternative access of ischemic myocardium: implications for myocardial protection, myocardial gene transfer and angiogenesis , 2000, Zeitschrift für Kardiologie.
[18] R. Balice-Gordon,et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector , 1999, Nature Medicine.
[19] E. Marbán,et al. Ultrarapid, highly efficient viral gene transfer to the heart. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Strumpf,et al. Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. , 1996, The Annals of thoracic surgery.